Rethinking Psychiatry:
History, Science, and the Long-term Effects of Psychiatric Medications

Robert Whitaker
May 2016
The introduction of chlorpromazine into asylum medicine in 1955 “initiated a revolution in psychiatry, comparable to the introduction of penicillin in general medicine.”

--Edward Shorter, A History of Psychiatry
The Disabled Mentally Ill in the United States

(under government care)

Per 100,000 population

U.S. Disability in the Prozac Era

Millions of adults, 18 to 66 years old

Source: U.S. Social Security Administration Reports, 1987-2010
Disability Due to Psychiatric Disorders in New Zealand, 1991-2010

Source: Statistics New Zealand, Annual reports, 1999-2010
Disability Due to Psychiatric Disorders in Australia, 1990-2011

Sickness and Disability Benefits for United Kingdom, 1998-2014

About two-thirds of the claims were for a depressive or anxiety disorder.

New Cases of Disability in Denmark Due to Mental Illness

Percentage of All New Disability Cases in Sweden That Are Due to Mental Illness

The Beauty Of Science

Making the Case for Selective Use of Antipsychotics
The Evidence for Antipsychotics

Short-term Use

Antipsychotics reduce target symptoms of a disorder better than placebo in six-week trials.

Long-term Use

In relapse studies, those withdrawn from the medications relapse at a higher rate than those maintained on the medications.

Clinical Perceptions

The physician sees that the medications often work upon initial use, and sees that patients often relapse when they go off the medications.
What’s Missing From The Evidence Base?

A. It does not provide evidence that medications improve the long-term course of schizophrenia (or other psychotic disorders,) particularly in regard to functional outcomes.

B. The relapse studies may reflect risks associated with drug-withdrawal effects, rather than just the return of the natural course of the disorder.

C. Physicians today no longer have clinical experience with the long-term course of schizophrenia patients off medication.
Recognition that the Evidence Base For Long-term Use of Antipsychotics is Lacking

“After fifty years of neuroleptics, are we able to answer the following simple question: Are neuroleptics effective in treating schizophrenia? [There is] no compelling evidence on the matter, when ‘long-term’ is considered.”

And:

“If we wish to base psychiatry on evidence-based medicine, we run a genuine risk in taking a close look at what has long been considered fact.”

The Case For Selective Use of Antipsychotics

A review of the outcomes literature for antipsychotics reveals:

1. There is a subset of first-episode psychotic patients who, if treated with psychosocial care but without antipsychotics, can recover.

2. There is a significant percentage of patients diagnosed with schizophrenia who, once they become stable on antipsychotics, can then successfully withdraw from the medications.

3. There is evidence that, over the long-term, antipsychotics may induce changes in the brain that may make a person more biologically vulnerable to psychosis, which provides additional reason for adopting a selective use model.

4. In 1992, a psychiatric district in northern Finland adopted a selective-use protocol for first episode patients, and it now has the best reported long-term outcomes in the developed world.
Schizophrenia Outcomes in the Decade Before Antipsychotics, 1945-1955

- At end of three years following hospitalization, 73% of first-episode patients admitted to Warren State Hospital from 1946 to 1950 were living in the community.

- At the end of six years following hospitalization, 70% of 216 first-episode patients admitted to Delaware State Hospital from 1948 to 1950 were living in the community.

- In studies of schizophrenia patients in England, where the disorder was more narrowly defined, after five years 33% enjoyed a complete recovery, and another 20 percent a social recovery, which meant they could support themselves and live independently.

Discharge Rates for Schizophrenia Patients in California, 1956-1957

In 1956:

- There were 673 patients newly hospitalized for schizophrenia.
- Of this group, 428 were treated without antipsychotics.
- Sixty-seven percent of the unmedicated patients were discharged within six months, and 88% at 18 months.

In 1957:

- There were 740 patients newly hospitalized for schizophrenia.
- Of this group, 384 were treated without antipsychotics.
- Seventy-one percent of the unmedicated patients were discharged within six months.

A Retrospective Comparison of Outcomes in Pre-Drug and Drug Era

Relapse Rates Within Five Years of Discharge

1947 cohort: 55%
1967 cohort: 69%

Functional Outcomes

1947 cohort: 76% were successfully living in the community at end of five years

1967 cohort: They were much more “socially dependent”—on welfare and needing other forms of support—than the 1947 cohort.

Bockoven’s Conclusion:

“Rather unexpectedly, these data suggest that psychotropic drugs may not be indispensable. Their extended use in aftercare may prolong the social dependency of many discharged patients.”
# Rappaport’s Study: Three-Year Outcomes

<table>
<thead>
<tr>
<th>Medication use (in hospital/after discharge)</th>
<th>Number of Patients</th>
<th>Severity of Illness (1= best outcome; 7 = worst outcome)</th>
<th>Rehospitalization</th>
</tr>
</thead>
<tbody>
<tr>
<td>No meds/off</td>
<td>24</td>
<td>1.7</td>
<td>8%</td>
</tr>
<tr>
<td>Antipsychotic/off</td>
<td>17</td>
<td>2.79</td>
<td>47%</td>
</tr>
<tr>
<td>No meds/on</td>
<td>17</td>
<td>3.54</td>
<td>53%</td>
</tr>
<tr>
<td>Antipsychotic/on</td>
<td>22</td>
<td>3.51</td>
<td>73%</td>
</tr>
</tbody>
</table>

Source: Rappaport, M. “Are there schizophrenics for whom drugs may be unnecessary or contraindicated?” *Int Pharmacopsychiatry* 13 (1978):100-11.
Rappaport’s Conclusion:

“Our findings suggest that antipsychotic medication is not the treatment of choice, at least for certain patients, if one is interested in long-term clinical improvement. Many unmedicated-while-in-hospital patients showed greater long-term improvement, less pathology at follow-up, fewer rehospitalizations, and better overall functioning in the community than patients who were given chlorpromazine while in the hospital.”
Loren Mosher’s Soteria Project

Results:

At end of two years, the Soteria patients had “lower psychopathology scores, fewer [hospital] readmissions, and better global adjustment.”

In terms of antipsychotic use, 42% had never been exposed to the drugs, 39% had used them temporarily, and 19% had used them regularly throughout the two-year followup.

Loren Mosher’s Conclusion

“Contrary to popular views, minimal use of antipsychotic medications combined with specially designed psychosocial intervention for patients newly identified with schizophrenia spectrum disorder is not harmful but appears to be advantageous. We think the balance of risks and benefits associated with the common practice of medicating nearly all early episodes of psychosis should be re-examined.”
William Carpenter’s In-House NIMH Study, 1977

• Compared 27 schizophrenia patients treated with psychotherapy and no antipsychotics to 22 patients treated with both psychotherapy and antipsychotics.

• Those treated without drugs were discharged sooner (108 days on average versus 126 days.)

• 35% of the group treated without drugs in the hospital relapsed within a year after discharge, versus 45% of the medicated group.

• The unmedicated group also suffered less from depression, blunted emotions, and retarded movements.

“Patients reported experiencing more anguish with our treatment approach, whereas they felt a greater sense of frustration and of being ‘frozen in the psychosis’ in settings emphasizing drug treatment . . . insofar as the psychotic break contains potential for helping the patient alter pathological conflicts within himself and establish a more adaptive equilibrium with his environment, our present-day practice of immediate and massive pharmacological intervention may be exacting a price in terms of producing ‘recovered’ patients with greater rigidity of character structure who are less able to cope with subsequent life stresses.”

--William Carpenter
William Carpenter Raises a Question:

“There is no question that, once patients are placed on medication, they are less vulnerable to relapse if maintained on neuroleptics. But what if these patients had never been treated with drugs to begin with? . . . We raise the possibility that antipsychotic medication may make some schizophrenic patients more vulnerable to future relapse than would be the case in the normal course of the illness. Thus, as with tardive dyskinesia, we may have a situation where neuroleptics increase the risk for subsequent illness but must be maintained to prevent this risk from becoming manifest.”

The Dopamine Supersensitivity Theory

Dopamine function before exposure to antipsychotics

Presynaptic neuron

Dopamine

Dopamine receptors

Postsynaptic neuron
Dopamine function after exposure to antipsychotics

Antipsychotic blocks receptors

Brain increases receptors to compensate for drug blockade
The Consequences of Dopamine Supersensitivity

“Neuroleptics can produce a dopamine supersensitivity that leads to both dyskinetic and psychotic symptoms . . . An implication is that the tendency toward psychotic relapse in a patient who has developed such a supersensitivity is determined by more than just the normal course of the illness.”

Guy Chouinard and Barry Jones, McGill University

Study of Drug-Induced Tardive Psychosis

In 1982, Chouinard and Jones reported that 30% of the 216 schizophrenia outpatients they studied showed sign of tardive psychosis, which meant their psychosis was becoming chronic. When this happens, they wrote, “the illness appears worse” than ever before. “New schizophrenic symptoms of greater severity will appear.”

WHO Cross-Cultural Studies, 1970s/1980s

• In both studies, which measured outcomes at the end of two years and five years, the patients in the three developing countries, India, Nigeria, and Colombia, had a “considerably better course and outcome” than in the U.S. and six other developed countries.

• The WHO researchers concluded that “being in a developed country was a strong predictor of not attaining a complete remission.”

• They also found that “an exceptionally good social outcome characterized the patients” in developing countries.

Medication usage:

16% of patients in the developing countries were regularly maintained on antipsychotics, versus 61% of the patients in rich countries.

15-year to 20-year followup:

The “outcome differential” held up for “general clinical state, symptomatology, disability, and social functioning.” In the developing countries, 53% of schizophrenia patients were “never psychotic” anymore, and 73% were employed.

The Vermont Longitudinal Study

Courtenay Harding conducted a 30-year followup of 269 schizophrenia patients released from the back wards of Vermont State Hospital in the 1950s.

In 1987, Harding reported that “at least 25% to 50% were completely off their medications, suffered no further signs and symptoms of schizophrenia, and were functioning well.”

Harding concluded: It is a “myth” that schizophrenia “patients must be on medication all their lives. It may be a small percentage who need medication indefinitely.”

Martin Harrow’s Long-Term Study of Psychotic Patients

Patient Enrollment

- 64 schizophrenia patients
- 81 patients with other psychotic disorders
  - 37 psychotic bipolar patients
  - 28 unipolar psychotic patients
  - 16 other milder psychotic disorders

- Median age of 22.9 years at index hospitalization
- Previous hospitalization
  - 46% first hospitalization
  - 21% one previous hospitalization
  - 33% two or more previous hospitalizations

Anxiety Symptoms of Schizophrenia Patients

Cognitive Function of Schizophrenia Patients

Scores on abstract thinking

Best

Worst

2-years 4.5 years 7.5 years 10 years 15 years 20 years

Psychotic Symptoms in Schizophrenia Patients Over the Long Term

Relapse Rates Once Patients Are Stable

<table>
<thead>
<tr>
<th>Duration</th>
<th>Off Antipsychotics</th>
<th>On Antipsychotics</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.5 to 10 years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 to 15 years</td>
<td></td>
<td>56%</td>
</tr>
<tr>
<td>15 to 20 years</td>
<td></td>
<td>28%</td>
</tr>
</tbody>
</table>

Long-term Recovery Rates for Schizophrenia Patients

More on Recovery Rates

Medication compliant patients throughout 20 years: 17% had one period of recovery.

Those off antipsychotics by year two who then remained off throughout next 18 years: 87% had two or more sustained periods of recovery.

Global Adjustment of Schizophrenia Patients

Spectrum of Outcomes in Harrow’s Study

On Antipsychotics
- Recovered: 5%
- Fair: 46%
- Uniformly Poor: 49%

Off Antipsychotics
- Recovered: 40%
- Fair: 44%
- Uniformly Poor: 16%

“In addition, global outcome for the group of patients with schizophrenia who were on antipsychotics was compared with the off-medication schizophrenia patients with similar prognostic status. Starting with the 4.5-year follow-up and extending to the 15-year follow-up, the off-medication subgroup tended to show better global outcomes at each followup.”

Martin Harrow, page 411.
“I conclude that patients with schizophrenia not on antipsychotic medication for a long period of time have significantly better global functioning than those on antipsychotics.”

--Martin Harrow, American Psychiatric Association annual meeting, 2008
Global Adjustment of “Other Psychotic” Patients

Global Adjustment of All Psychotic Patients

“How unique is it that the apparent efficacy of antipsychotics could diminish over time or become ineffective or harmful? There are many examples for other medications of similar long-term effects, with this often occurring as the body readjusts, biologically, to the medications.”

--Martin Harrow, 2013
Harrow, continued:

Longitudinal studies “clearly indicate that not all schizophrenia patients need continuous antipsychotics for a prolonged period, providing extensive evidence of sample of medication-free schizophrenia patients with favorable outcomes. Is it at least a moderate-sized number of schizophrenia patients who do well, longitudinally, without medications?”
A Call to Rethink Antipsychotics

“It is time to reappraise the assumption that antipsychotics must always be the first line of treatment for people with psychosis. This is not a wild cry from the distant outback, but a considered opinion by influential researchers . . . [there is] an increasing body of evidence that the adverse effects of [antipsychotic] treatment are, to put it simply, not worth the candle.”

--Peter Tyrer, Editor

*British Journal of Psychiatry, August 2012*
A Model for Selective Use of Antipsychotics

The practice in Western Lapland, Finland (since 1992)

- First-episode patients are not immediately put on antipsychotics. Instead, they are treated with intensive psychosocial care, and benzodiazepines on an as-needed basis, to help people sleep.

- As long as patients are getting better, antipsychotics are not used. If, after several weeks, they are not improving, then low doses of an antipsychotic are prescribed.

- After the medicated patients are stabilized, there is an effort--after six months or so--to gradually withdraw them from the medication.
# Outcomes with Selective Use of Antipsychotics

Five-Year Outcomes for First-episode Psychotic Patients in Finnish Western Lapland Treated with Open-Discourse Therapy

<table>
<thead>
<tr>
<th>Patients (N=75)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Schizophrenia (N=30)</td>
<td></td>
</tr>
<tr>
<td>Other psychotic disorders (N=45)</td>
<td></td>
</tr>
</tbody>
</table>

## Antipsychotic Use

<table>
<thead>
<tr>
<th>Antipsychotic use</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Never exposed to antipsychotics</td>
<td>67%</td>
</tr>
<tr>
<td>Occasional use during five years</td>
<td>33%</td>
</tr>
<tr>
<td>Ongoing use at end of five years</td>
<td>20%</td>
</tr>
</tbody>
</table>

## Psychotic Symptoms

<table>
<thead>
<tr>
<th>Psychotic symptoms</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Never relapsed during five years</td>
<td>67%</td>
</tr>
<tr>
<td>Asymptomatic at five-year followup</td>
<td>79%</td>
</tr>
</tbody>
</table>

## Functional Outcomes at Five Years

<table>
<thead>
<tr>
<th>Functional outcomes at five years</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Working or in school</td>
<td>73%</td>
</tr>
<tr>
<td>Unemployed</td>
<td>7%</td>
</tr>
<tr>
<td>On disability</td>
<td>20%</td>
</tr>
</tbody>
</table>

On importance of using neuroleptics in a selective fashion:

“I am confident of this idea. There are patients who may be living in a quite peculiar way, and they may have psychotic ideas, but they still can hang on to an active life. But if they are medicated, because of the sedative action of the drugs, they lose this ‘grip on life,’ and that is so important. They become passive, and they no longer take care of themselves.”

--Jaakko Seikkula
What Percentage of First-Episode Psychotic Patients Could Recover Without Exposure to Antipsychotics?

1945-55: More than 70% of first-episode patients discharged within 18 months.

1956-57: 67% of hospitalized patients discharged within six months.

Rappaport (1978): 58% (24 of 41) still off medication and doing well at end of three years.

Mosher (1970s): 42% never exposed to antipsychotics at end of two years.

What Percentage of Schizophrenia Patients Might Not Need Maintenance Treatment?

1945-55: 70% of first-episode patients living in community at 5 years.

Bockoven: 76% living in community at five years.

Rappaport: 51% of patients (41 of 80) at three years.

Mosher: 81% at end of two years.

Baldessarini: 68% stable after six months.

Harding: 25% to 50% at 30 years.

Harrow: 33% (21 of 64)

Western Lapland: 80% at five years.